Concepedia

Publication | Open Access

Improved Survival with Bevacizumab in Advanced Cervical Cancer

DOIFull Paper Access

1.5K

Citations

28

References

2014

Year

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão,
New England Journal of Medicine

Abstract

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

References

YearCitations

Page 1